Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Conditions

• Immunotherapy
• Gastric Cancer (GC)
• Radiotherapy
• Neoadjuvant Therapy
• Neoadjuvant Chemoimmunotherapy

Interventions

• DRUG: Iparomlimab and Tuvonralimab
• DRUG: Oxaliplatin
• DRUG: Tegafur
• RADIATION: Radiotherapy

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University